On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain

  title={On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain},
  author={{\'A}lvaro Briz-Red{\'o}n and {\'A}ngel Serrano-Aroca},
  journal={Stochastic Environmental Research and Risk Assessment},
  pages={1 - 8}
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19), has led to the deepest global health and economic crisis of the current century. This dramatic situation has forced the public health authorities and pharmaceutical companies to develop anti-COVID-19 vaccines in record time. Currently, almost 80% of the population are vaccinated with the required number of doses in Spain. Thus, in this paper, COVID-19 incidence and lethality… 

Figures from this paper


The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission
Transmission reductions declined over time since second vaccination, for Delta reaching similar levels to unvaccinated individuals by 12 weeks for ChAdOx1 and attenuating substantially for BNT162b2.
The biological and clinical significance of emerging SARS-CoV-2 variants
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel spike protein mutations that are influencing the epidemiological and clinical aspects of the COVID-19 pandemic.
Estimation of the case fatality rate based on stratification for the COVID-19 outbreak
By the COVID-19 cases of China, South Korea and the United States, it is numerically show the proposed stratification-based estimator plays a role of providing an early warning about the severity of a epidemiological disease that estimates the final case fatality rate accurately and shows faster convergence to the final Case Fatality rate.
Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
A vaccine that modestly reduces the risk of clinical disease, but greatly decreases infectiousness, can be more beneficial at the population level than a vaccine that prevents most symptomatic SARS-CoV-2 infections, but does little to reduce onward transmission.
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2 outcomes declined, and the nationwide public-health impact following the widespread introduction of the vaccine was evaluated.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents
It is shown that initial VLs at diagnosis in symptomatic children is comparable to those in adults, and that symptomaticChildren of all ages shed infectious virus in early acute illness.
Shedding of Infectious SARS-CoV-2 Despite Vaccination
Swab data from 699 swab specimens collected in Wisconsin between 29 June through 31 July 2021 and tested with a qualitative assay by a single contract laboratory showed increased prevalence of Delta variants, and vaccination status was determined via self-reporting and state immunization records.
Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021
The screening method and population-based data sources were used to obtain estimates of mRNA COVID-19 vaccine effectiveness for elderly LTCF residents, and the estimates were 71%, 88%, and 97% against SARS-CoV-2 infections (symptomatic and asymptomatic), and CO VID-19 hospitalisations and deaths, respectively.
Transmission event of SARS-CoV-2 delta variant reveals multiple vaccine breakthrough infections
Delta variant may pose the highest risk out of any currently circulating SARS-CoV-2 variants, with previously described increased transmissibility over alpha variant and now, possible vaccine breakthrough.